Table 2.
Five years survival and treatment according subtypes
| Luminal 1 (n = 63) | Luminal 2 (n = 10) | Triple negative (n = 113) | Nonluminal HER-2-positive (n = 56) | Comparison using χ 2 (p- value) | ||
|---|---|---|---|---|---|---|
| Number (%) | Number (%) | Number (%) | Number (%) | |||
| Survival | DFS | 35(55.6) | 5(50.0) | 21(18.6) | 8(14.3) | <0.001a |
| Relapse | 1(1.6) | 1(10.0) | 17(15.0) | 10(17.9) | ||
| Death | 27(42.9) | 4(40.0) | 75(66.4) | 38(67.9) | ||
| Adjuvant therapy | FAC | 0(0.0) | 0(0.0) | 79(69.9) | 49(87.5) | <0.001a |
| TAC | 0(0.0) | 0(0.0) | 34(30.1) | 1(1.8) | ||
| FAC+HT | 63(100.0) | 7(70.0) | 0(0.0) | 0(0.0) | ||
| FAC+HT+Trastuzumab | 0(0.0) | 3(30.0) | 0(0.0) | 0(0.0) | ||
| TAC+Trastuzumab | 0(0.0) | 0(0.0) | 0(0.0) | 6(10.7) | ||
| Neoadjuvant therapy | Yes | 8(12.7) | 1(10.0) | 86(76.1) | 24(42.9) | <0.001a |
| No | 55(87.3) | 9(90.0) | 27(23.9) | 32(57.1) |
aStatistically significant